Global Market Size, Forecast, and Trend Highlights Over 2025 – 2037
Preeclampsia Diagnostics Market size was over USD 1.38 billion in 2024 and is anticipated to exceed USD 2.08 billion by the end of 2037, witnessing over 3.2% CAGR during the forecast period i.e., between 2025-2037. In the year 2025, the industry size of preeclampsia diagnostics is evaluated at USD 1.42 billion.
The growth of this market can be propelled by the increasing prevalence of preterm births. In least-developed countries such as Bangladesh, Afghanistan and Central Africa, infections, malaria, and high teenage pregnancy rates are the main causes of premature births. As per a report of World Health Organization, 14 million births were pre-termed in 2020 with 1 million of death out of complications.
The main trend of the market is being recognized as an increasing need for companion diagnostics. With the growing need for an understanding of patient needs and the provision of personalized medicinal products, there is increasing demand for companion diagnostics. This trend will be more widespread and is expected to allow the entry of POC products including laboratory tests for preeclampsia into new markets. This further leads to disease management, patient satisfaction, and treatment adherence. All these, factors are expected to boost the market growth of preeclampsia diagnostics in the estimated period.
Preeclampsia Diagnostics Sector: Growth Drivers and Challenges
Growth Drivers
- Market Expansion in Emerging Economies – The preeclampsia diagnostics market is growing rapidly in emerging economies such as India and China. This is due to several factors such as rising incomes, increasing access to healthcare and increasing awareness about preeclampsia. This factor is anticipated to drive the growth of the preeclampsia diagnostics market in the anticipated time period.
- Development of Innovative Tests - The development of early diagnostic tests for preeclampsia will help reduce maternal and neonatal mortality. Awareness of pre-eclampsia has increased recently, mainly due to campaigns by patient advocacy groups and welfare associations. This remains an important factor providing profitable growth opportunities for innovative test development given the significant unmet need for diagnosing pre-eclampsia worldwide.
Challenges
- Lack of Reimbursement - The lack of reimbursement will limit the market growth during the forecast period. Most health insurance policies do not cover reimbursement for preeclampsia tests. Lack of reimbursement policy and high cost pose barriers to adoption of preeclampsia testing. Some state and federal officials as well as health officials have publicly encouraged payers to review their insurance policies for Diagnostics for preeclampsia. However, the market still lacks reimbursement services for preeclampsia testing. Such factors limit the growth of the market. Therefore, these factors are expected to restrict the market growth of preeclampsia diagnostics market in the projected timeframe.
- High Cost of Preeclampsia Diagnostics is Expected to Hamper the Market Growth in Upcoming Period.
- Lack of Skilled Professionals is Estimated to Restrict the Market Expansion in Future Time.
Preeclampsia Diagnostics Market: Key Insights
|
Base Year |
2024 |
|
Forecast Year |
2025-2037 |
|
CAGR |
3.2% |
|
Base Year Market Size (2024) |
USD 1.38 billion |
|
Forecast Year Market Size (2037) |
USD 2.08 billion |
|
Regional Scope |
|
Preeclampsia Diagnostics Segmentation
Product (Instrument, Consumables)
Based on product, the consumables segment is estimated to hold the highest market share of 60% by the end of 2037. The selection and enrichment of laboratory tests for preeclampsia must be performed with the aid of consumables. Reagents used in laboratory studies for preeclampsia are chemical substances or mixtures. The growth in the consumables sector has been driven by factors like low costs and increasing consumption frequency. Various growth strategies such as the launch of new products, Strategic Alliances, and M&As are adopted by market players in order to maintain their competitiveness. New players are being encouraged to enter the market on the grounds of moderate market growth potential and access to distribution channels.
End User (Hospitals, Clinics, Diagnostic Centers)
Based on end user, the hospital segment is estimated to grow substantially during the time period between 2024-2037. Hospitals have the most comprehensive range of Diagnostics services available comprising those for preeclampsia. They are the primary location where pregnant women are cared for so they are most likely places where preeclampsia will be diagnosed and managed. Furthermore, the increasing prevalence of preeclampsia is estimated to drive the growth of the the segment in the projected period. Around 2-8% of pregnant women experience preeclampsia during their pregnancy worldwide.
Our in-depth analysis of the global market includes the following segments:
|
Product |
|
|
End User
|
|
|
Test |
|
Want to customize this research report as per your requirements? Our research team will cover the information you require to help you take effective business decisions.
Customize this ReportPreeclampsia Diagnostics Industry - Regional Synopsis
North American Market Forecast
The North America preeclampsia laboratory market is predicted to hold the largest market share of 35% during the forecast period. The growth of the market in the country is due to factors such as increasing focus on drug delivery services and vaccine discovery and development, recent advancements in biotechnology and pharmaceutical research as well as the presence of many suppliers. In Canada, growing awareness of maternal and fetal health care through the Canadian Fetal Health Surveillance Program and the Canadian Premature Babies Foundation (CPBF) has led to rapid adoption of screening productand s, pre-eclampsia testing in the laboratory at obstetrics departments.
Asia Pacific Market Statistics
The market in the Asia Pacific region is expected to grow substantially during the time period between 2024-2037. The growth of this market can be attributed owing to increasing population of women in reproductive age in the region. Besides this, escalating research and development activities, growing technological advancements and presence of biotechnology companies in the region is boosting the market expansion of preeclampsia diagnostics market on the forecast period.
Companies Dominating the Preeclampsia Diagnostics Landscape
- ACON Laboratories Inc.
- Company Overview
- Business Strategy
- Key Product Offerings
- Financial Performance
- Key Performance Indicators
- Risk Analysis
- Recent Development
- Regional Presence
- SWOT Analysis
- Bio Rad Laboratories Inc.
- BioCheck Inc.
- bioMerieux SA
- Cardinal Health Inc.
- Diabetomics Inc.
- F. Hoffmann La Roche Ltd.
- Thermo Fisher Inc.
- Biora Therapeutics Inc
- Sysmex Corporation
- Hitachi Ltd.
- Fujirebio Diagnostics
- Siemens Healthineers AG
- Fujifilm Corporation
In the News
- Thermo Fisher Scientific Inc., a world leader in serving science, announced in May 2023 that the U.S. Food and Drug Administration approved Thermo Scientific B·R·A·H· M·S PlGF plus KRYPTOR and B ·R·A·H . ·M·S sFlt-1 KRYPTOR novel biomarker, the first and only immunoassay to receive breakthrough designation and be validated for risk assessment and clinical management of preeclampsia, a serious complications of pregnancy.
- Biora Therapeutics, Inc., a biotechnology company that reimagines therapy delivery, has entered into an agreement to license Avero Diagnostics' Preeclampsia Ruleout test previously carried out at Northwest Pathology Company for commercial development of the product.
Author Credits: Radhika Pawar
- Report ID: 4412
- Published Date: Oct 22, 2024
- Report Format: PDF, PPT
